256 related articles for article (PubMed ID: 38362504)
1. Synthetic biology for combating leishmaniasis.
Khandibharad S; Singh S
Front Microbiol; 2024; 15():1338749. PubMed ID: 38362504
[TBL] [Abstract][Full Text] [Related]
2. An appraisal of the scientific current situation and new perspectives in the treatment of cutaneous leishmaniasis.
Briones Nieva CA; Cid AG; Romero AI; García-Bustos MF; Villegas M; Bermúdez JM
Acta Trop; 2021 Sep; 221():105988. PubMed ID: 34058160
[TBL] [Abstract][Full Text] [Related]
3. Leishmaniasis: prevention, parasite detection and treatment.
Kobets T; Grekov I; Lipoldova M
Curr Med Chem; 2012; 19(10):1443-74. PubMed ID: 22360481
[TBL] [Abstract][Full Text] [Related]
4. Virulence factors of Leishmania parasite: Their paramount importance in unraveling novel vaccine candidates and therapeutic targets.
Kumari D; Mahajan S; Kour P; Singh K
Life Sci; 2022 Oct; 306():120829. PubMed ID: 35872004
[TBL] [Abstract][Full Text] [Related]
5. [Approaches and problems in vaccine development against leishmaniasis].
Allahverdiyev A; Bağirova M; Cakir Koç R; Oztel ON; Elçıçek S; Ateş SC; Karaca TD
Turkiye Parazitol Derg; 2010; 34(2):122-30. PubMed ID: 20597059
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications.
Gannavaram S; Dey R; Avishek K; Selvapandiyan A; Salotra P; Nakhasi HL
Front Immunol; 2014; 5():241. PubMed ID: 24904589
[TBL] [Abstract][Full Text] [Related]
7. Perspectives From Systems Biology to Improve Knowledge of
Horácio ECA; Hickson J; Murta SMF; Ruiz JC; Nahum LA
Front Cell Infect Microbiol; 2021; 11():653670. PubMed ID: 33996631
[TBL] [Abstract][Full Text] [Related]
8. From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection.
Volpedo G; Huston RH; Holcomb EA; Pacheco-Fernandez T; Gannavaram S; Bhattacharya P; Nakhasi HL; Satoskar AR
Expert Rev Vaccines; 2021 Nov; 20(11):1431-1446. PubMed ID: 34511000
[TBL] [Abstract][Full Text] [Related]
9. Developments in diagnosis and antileishmanial drugs.
Bhargava P; Singh R
Interdiscip Perspect Infect Dis; 2012; 2012():626838. PubMed ID: 23118748
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Vaccines Against Leishmania Based on Patent Applications.
Thomaz-Soccol V; Ferreira da Costa ES; Karp SG; Junior Letti LA; Soccol FT; Soccol CR
Recent Pat Biotechnol; 2018; 12(1):21-32. PubMed ID: 28494723
[TBL] [Abstract][Full Text] [Related]
11. Genetically modified live attenuated parasites as vaccines for leishmaniasis.
Selvapandiyan A; Duncan R; Debrabant A; Lee N; Sreenivas G; Salotra P; Nakhasi HL
Indian J Med Res; 2006 Mar; 123(3):455-66. PubMed ID: 16778323
[TBL] [Abstract][Full Text] [Related]
12. Recent patents in the treatment and prevention of leishmaniasis.
Shahid SK
Pharm Pat Anal; 2023 Sep; 12(5):237-248. PubMed ID: 38063376
[TBL] [Abstract][Full Text] [Related]
13. Anti-leishmanial Nanotherapeutics: A Current Perspective.
Shah A; Gupta SS
Curr Drug Metab; 2019; 20(6):473-482. PubMed ID: 30360732
[TBL] [Abstract][Full Text] [Related]
14. Molecular Targets for Chalcones in Antileishmanial Drug Discovery.
de Santiago-Silva KM; da Silva Gomes GF; Perez CC; da Silva Lima CH; de Lima Ferreira Bispo M
Mini Rev Med Chem; 2023; 23(14):1414-1434. PubMed ID: 36705240
[TBL] [Abstract][Full Text] [Related]
15. In Silico Design of Recombinant Chimera T Cell Peptide Epitope Vaccines for Visceral Leishmaniasis.
Machado AS; Martins VT; Humbert MV; Christodoulides M; Coelho EAF
Methods Mol Biol; 2022; 2410():463-480. PubMed ID: 34914063
[TBL] [Abstract][Full Text] [Related]
16. Leishmania lipophosphoglycan components: A potent target for synthetic neoglycoproteins as a vaccine candidate for leishmaniasis.
Mohammed ASA; Tian W; Zhang Y; Peng P; Wang F; Li T
Carbohydr Polym; 2020 Jun; 237():116120. PubMed ID: 32241437
[TBL] [Abstract][Full Text] [Related]
17. Host immune response against leishmaniasis and parasite persistence strategies: A review and assessment of recent research.
Elmahallawy EK; Alkhaldi AAM; Saleh AA
Biomed Pharmacother; 2021 Jul; 139():111671. PubMed ID: 33957562
[TBL] [Abstract][Full Text] [Related]
18. Development of nano-carriers for
Askarizadeh A; Badiee A; Khamesipour A
Expert Opin Drug Deliv; 2020 Feb; 17(2):167-187. PubMed ID: 31914821
[No Abstract] [Full Text] [Related]
19. Nanotechnology-aided diagnosis, treatment and prevention of leishmaniasis.
Kammona O; Tsanaktsidou E
Int J Pharm; 2021 Aug; 605():120761. PubMed ID: 34081999
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
